{"id":"W2563730090","doi":"10.1182/blood.v124.21.713.713","title":"Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Bone marrow; Essential thrombocythemia; Internal medicine; Gastroenterology; Fibrosis; Anemia; Ruxolitinib; Clinical endpoint; Polycythemia vera; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001366683,0.001175295,0.001279772,0.0002872545,0.0002958228,0.0006303888,0.000638861,0.001074582,0.006216477],"category_scores_gemma":[0.0008005911,0.0003511661,0.0009192738,0.0001806561,0.0005171608,0.0007392101,0.0003152884,0.002206553,0.0009258342],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004859408,"about_ca_system_score_gemma":0.0008391452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002838046,"about_ca_topic_score_gemma":0.001047298,"domain_scores_codex":[0.9997486,0.0001150962,0.00001129034,0.00004615845,0.00001947136,0.0000592927],"domain_scores_gemma":[0.9996299,0.00007262265,0.00007645533,0.00003041571,0.00002439231,0.0001661859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.72223,0.06268249,0.006396415,0.001120256,0.000697996,0.0003960731,0.0003048457,0.002356178,0.04569082,0.0007044772,0.008500778,0.1489196],"study_design_scores_gemma":[0.5161349,0.4647937,0.01002197,0.00005735987,0.0001921912,0.000347484,0.00003477168,0.001101342,0.002918766,0.0003708314,0.004001508,0.00002522276],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881945,0.001971373,0.0006375211,0.0006578541,0.000126578,0.003955076,0.001606736,0.0001242415,0.002726116],"genre_scores_gemma":[0.9860174,0.0009461252,0.00191276,0.001116247,0.0001883805,0.003722136,0.002515244,0.00002366531,0.003558018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006216477,"threshold_uncertainty_score":0.02079618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01691741954328189,"score_gpt":0.2784163516495287,"score_spread":0.2614989321062468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}